{"id":"W4387361131","doi":"10.1210/jendso/bvad114.1890","title":"FRI545 Durability Of Treatment Response With VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor, In Patients With Thyroid Eye Disease (TED): Phase 1/2 Clinical Study","year":2023,"lang":"en","type":"article","venue":"Journal of the Endocrine Society","topic":"Ophthalmology and Eye Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Medicine; Placebo; Tolerability; Stock options; Clinical trial; Clinical endpoint; Internal medicine; Antagonist; Receptor; Adverse effect; Pharmacology; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010677,0.0004224068,0.0008590549,0.0002135572,0.0001974597,0.0005413133,0.0004734687,0.0006407846,0.003329052],"category_scores_gemma":[0.0007118634,0.0001423165,0.0008798874,0.0001910176,0.0002987671,0.0004094929,0.0001577117,0.0009868654,0.0006362661],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000680024,"about_ca_system_score_gemma":0.0004151286,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00108084,"about_ca_topic_score_gemma":0.002562244,"domain_scores_codex":[0.999719,0.00008295408,0.00002639232,0.00005414878,0.00005531174,0.00006233616],"domain_scores_gemma":[0.9996321,0.00008648256,0.00008389623,0.00002968034,0.00002619717,0.0001416456],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4765307,0.01491697,0.03837122,0.001885094,0.00332542,0.0004053961,0.0002588225,0.001814916,0.08135041,0.0003512435,0.009848949,0.370941],"study_design_scores_gemma":[0.2071535,0.5442016,0.2191393,0.0002429762,0.002466464,0.0009329636,0.0001553148,0.00169107,0.01132638,0.0002991855,0.01229604,0.00009524854],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9800188,0.01414255,0.0002193015,0.0003367733,0.0001163437,0.0003001286,0.00147046,0.00005360541,0.003341937],"genre_scores_gemma":[0.9929364,0.002273268,0.0002928366,0.0004333172,0.00009877511,0.0002254467,0.001630788,0.000009063539,0.002100138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003329052,"threshold_uncertainty_score":0.01113677,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02023059721447011,"score_gpt":0.3860755338942498,"score_spread":0.3658449366797796,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}